Nan Fung Trinity HK Ltd. Acquires 9,842 Shares of Protagonist Therapeutics, Inc. $PTGX

Nan Fung Trinity HK Ltd. grew its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 7.3% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 144,892 shares of the company’s stock after purchasing an additional 9,842 shares during the quarter. Nan Fung Trinity HK Ltd.’s holdings in Protagonist Therapeutics were worth $9,625,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. BVF Inc. IL grew its position in Protagonist Therapeutics by 24.7% during the second quarter. BVF Inc. IL now owns 3,211,041 shares of the company’s stock valued at $177,474,000 after buying an additional 636,026 shares during the period. State Street Corp boosted its stake in Protagonist Therapeutics by 18.5% in the second quarter. State Street Corp now owns 3,207,543 shares of the company’s stock valued at $177,281,000 after acquiring an additional 500,924 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Protagonist Therapeutics by 1.5% during the 2nd quarter. Geode Capital Management LLC now owns 1,444,230 shares of the company’s stock valued at $79,833,000 after acquiring an additional 20,671 shares during the period. Adage Capital Partners GP L.L.C. grew its position in shares of Protagonist Therapeutics by 218.0% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 1,092,262 shares of the company’s stock valued at $60,369,000 after acquiring an additional 748,758 shares during the period. Finally, Commodore Capital LP purchased a new stake in shares of Protagonist Therapeutics during the 2nd quarter worth approximately $59,415,000. 98.63% of the stock is owned by hedge funds and other institutional investors.

Protagonist Therapeutics Trading Up 2.6%

PTGX stock opened at $81.80 on Friday. The firm has a 50 day moving average of $86.26 and a 200-day moving average of $72.71. The firm has a market capitalization of $5.11 billion, a P/E ratio of 131.94 and a beta of 2.26. Protagonist Therapeutics, Inc. has a 12 month low of $33.70 and a 12 month high of $96.54.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its earnings results on Thursday, November 6th. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.03). Protagonist Therapeutics had a return on equity of 6.86% and a net margin of 21.94%.The firm had revenue of $4.71 million for the quarter, compared to the consensus estimate of $5.41 million. Sell-side analysts predict that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the company. Citigroup upped their price objective on Protagonist Therapeutics from $98.00 to $115.00 and gave the company a “buy” rating in a research note on Monday, December 8th. Truist Financial upped their price target on Protagonist Therapeutics from $88.00 to $110.00 and gave the company a “buy” rating in a research report on Monday, January 5th. BMO Capital Markets reissued an “outperform” rating on shares of Protagonist Therapeutics in a report on Monday, October 13th. JPMorgan Chase & Co. upped their price objective on shares of Protagonist Therapeutics from $68.00 to $81.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Finally, BTIG Research reiterated a “buy” rating and set a $82.00 target price on shares of Protagonist Therapeutics in a research report on Tuesday, October 28th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $89.62.

Insider Transactions at Protagonist Therapeutics

In related news, insider Arturo Md Molina sold 13,151 shares of the business’s stock in a transaction dated Friday, January 23rd. The stock was sold at an average price of $82.42, for a total transaction of $1,083,905.42. Following the completion of the transaction, the insider directly owned 84,115 shares in the company, valued at $6,932,758.30. The trade was a 13.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Asif Ali sold 46,203 shares of the company’s stock in a transaction dated Tuesday, January 27th. The stock was sold at an average price of $83.13, for a total value of $3,840,855.39. Following the completion of the transaction, the chief financial officer owned 60,320 shares in the company, valued at $5,014,401.60. This represents a 43.37% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 165,167 shares of company stock valued at $13,732,039. 4.90% of the stock is currently owned by company insiders.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.